Health Advance will have exclusive licensing rights in the region for two Ibuprofen and botanical extract-based formulas.
Mitragyna speciosa is a tropical evergreen of the Rubiaceae family, used in Polyoxyfen
Health Advance has entered into a license agreement with Micro Medtech to acquire exclusive licensing rights in North America to cebidiofen and polyoxyfen formulas.
The formulas are specifically tied to the production of the neurotransmitters that enable management and enhancement to sensory response to pain and inflammation.
Cebidiofen is a product formulation for a medical food containing Ibuprofen and a unique botanical blend derived primarily from kava extract and cannabis extracts.
Polyoxyfen is a medical food containing Ibuprofen and a unique botanical blend derived primarily from kava and mitragyna speciose extracts.
Both are classified as Generally Recognised as Safe (GRAS) by the FDA.
Health Advance and Micro Medtech will begin working together with health claim experts Nutrasource Diagnostics to conduct a due diligence review and product development plan.
This will determine claims and optimal commercialisation strategies for cebidiofen and polyoxyfen.
The Product Development Plan process for both (provisional) patent-pending product formulations will take six to eight weeks to complete from the start date (March).
The plans will identify current gaps in the research and outline the clinical and regulatory pathways going forward.